Minimal Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
release_hnexf6mywjecta2kzrx4k2ds7a
by
W. Zeijlemaker, G.J. Schuurhuis
References
NOTE: currently batch computed and may include additional references sources, or be missing recent changes, compared to entity reference list.| Showing 1 - 30 of 144 references (in 251ms) | ||
|---|---|---|
[b0]via grobid |
Cornelissen, J. J., van Putten, W. L. J., Verdonck, L. F., Theobald, M., Jacky, E., Dae- nen, S. M., et al. (2007). Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom? Blood, 109(9), 3658-66.
| |
[b1]via grobid |
Cheson, B. D., Bennett, J. M., Kopecky, K. J., Büchner, T., Willman, C. L., Estey, E. H., et al. (2003). Revised recommendations of the International Working Group for Diag- nosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol, 21(24), 4642-9.
| |
[b2]via grobid |
Kern, W., Haferlach, C., Haferlach, T., & Schnittger, S. (2008). Monitoring of minimal residual disease in acute myeloid leukemia. Cancer, 112(1), 4-16.
| |
[b3]via grobid |
San, Miguel. J. F., Martinez, A., Macedo, A., Vidriales, M. B., López-Berges, C., Gon- zález, M., et al. (1997). Immunophenotyping investigation of minimal residual dis- ease is a useful approach for predicting relapse in acute myeloid leukemia patients. Blood, 90(6), 2465-70.
| |
[b4]via grobid |
Kern, W., Voskova, D., Schoch, C., Hiddemann, W., Schnittger, S., & Haferlach, T. (2004). Determination of relapse risk based on assessment of minimal residual dis- ease during complete remission by multiparameter flow cytometry in unselected pa- tients with acute myeloid leukemia. Blood, 104(10), 3078-85.
| |
[b5]via grobid |
Feller, N., van der Pol, M. A., van Stijn, A., Weijers, G. W. D., Westra, A. H., & Ever- tse, B. W. et al. (2004). MRD parameters using immunophenotypic detection methods are highly reliable in predicting survival in acute myeloid leukaemia. Leukemia , 18(8), 1380-90.
| |
[b6]via grobid |
Venditti, A., Buccisano, F., Del Poeta, G., Maurillo, L., Tamburini, A., Cox, C., et al. (2000). Level of minimal residual disease after consolidation therapy predicts out- come in acute myeloid leukemia. Blood, 96(12), 3948-52.
| |
[b7]via grobid |
Diez-Campelo, M., Pérez, J., Alcoceba, M., Richtmon, J., Vidriales, B., & San, Miguel. J. (2009). Minimal residual disease monitoring after allogeneic transplantation may help to individualize post-transplant therapeutic strategies in acute myeloid malig- nancies. Am J Hematol, 84(3), 149-52.
| |
[b8]via grobid |
Buccisano, F., Maurillo, L., Spagnoli, A., Del Principe, M. I., Ceresoli, . E., Lo, Coco. F., et al. (2009). Monitoring of minimal residual disease in acute myeloid leukemia. Curr Opin Oncol, 21(6), 582-8.
| |
[b9]via grobid |
Al-Mawali, A., Gillis, D., Lewis, I., & 20, . (2009). The use of receiver operating char- acteristic analysis for detection of minimal residual disease using five-color multi- parameter flow cytometry in acute myeloid leukemia identifies patients with high risk of relapse. Cytometry B Clin Cytom, 76(2), 91-101.
| |
[b10]via grobid |
Vidriales, M. B., San-Miguel, J. F., Orfao, A., Coustan-Smith, E., & Campana, D. (2003). Minimal residual disease monitoring by flow cytometry. Best Pract Res Clin Haematol, 16(4), 599-612.
| |
[b11]via grobid |
Baer, M. R., Stewart, C. C., Dodge, R. K., Leget, G., Sulé, N., Mrózek, K., et al. (2001). High frequency of immunophenotype changes in acute myeloid leukemia at relapse: implications for residual disease detection (Cancer and Leukemia Group B Study 8361). Blood, 97(11), 3574-80.
| |
[b12]via grobid |
Macedo, A., San, Miguel. J. F., Vidriales, M. B., López-Berges, M. C., García-Marcos, M. A., Gonzales, M., et al. (1996). Phenotypic changes in acute myeloid leukaemia: implications in the detection of minimal residual disease. J Clin Pathol, 49(1), 15-8.
| |
[b13]via grobid |
Grimwade, D., & Hills, R. K. (2009). Independent prognostic factors for AML out- come. Hematology Am Soc Hematol Educ Program:, 385-95.
| |
[b14]via grobid |
San, Miguel. J. F., Vidriales, M. B., López-Berges, C., Diaz-Mediavilla, J., Guttiérrez, N., Cañizo, C., et al. (2001). Early immunophenotypical evaluation of minimal resid- ual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification. Blood, 98(6), 1746-51.
| |
[b15]via grobid |
Maurillo, L., Buccisano, F., Del Principe, M. I., Del Poeta, G., Spagnoli, A., Panetta, P., et al. (2008). Toward optimization of postremission therapy for residual disease-posi- tive patients with acute myeloid leukemia. J Clin Oncol, 26(30), 4944-51.
| |
[b16]via grobid |
Terwijn, M., Kelder, A., van Putten, W. L. J., Snel, A. N., van der Velden, V. H. J., & Brooimans, R. A. et al. (2010). High prognostic impact of flowcytometric minimal re- sidual disease detection in acute myeloid leukemia: prospective data from the HOV- ON/SAKK 42a study. Blood (ASH Annual Meeting Abstracts)116:760.
| |
[b17]via grobid |
Sugimoto, T., Das, H., Imoto, S., Murayama, T., Gomyo, H., Chakraborty, S., et al. (2000). Quantitation of minimal residual disease in t(821)-positive acute myelogenous leukemia patients using real-time quantitative RT-PCR. Am J Hematol, 64(2), 101-6.
| |
[b18]via grobid |
Minimal Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia http://dx.doi.org/10.5772/52080
| |
[b19]via grobid |
Tobal, K., & Liu, Yin J.A. (1996). Monitoring of minimal residual disease by quantita- tive reverse transcriptase-polymerase chain reaction for AML1-MTG8 transcripts in AML-M2 with t(821). Blood, 88(10), 3704-9.
| |
[b20]via grobid |
Guerrasio, A., Pilatrino, C., De Micheli, D., Cilloni, D., Serra, A., Gottardi, E., et al. (2002). Assessment of minimal residual disease (MRD) in CBFbeta/MYH11-positive acute myeloid leukemias by qualitative and quantitative RT-PCR amplification of fu- sion transcripts. Leukemia, 16(6), 1176-81.
| |
[b21]via grobid |
Mitterbauer, G., Zimmer, C., Pirc-Danoewinata, H., Haas, O. A., Hojas, S., Schwar- zinger, I., et al. (2000). Monitoring of minimal residual disease in patients with MLL- AF6-positive acute myeloid leukaemia by reverse transcriptase polymerase chain reaction. Br J Haematol, 109(3), 622-8.
| |
[b22]via grobid |
Grimwade, D., Hills, R. K., Moorman, A. V., Walker, H., Chatters, S., Goldstone, A. H., et al. (2010). Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormali- ties among 5876 younger adult patients treated in the United Kingdom Medical Re- search Council trials. Blood, 116(3), 354-65.
| |
[b23]via grobid |
Erickson, P., Gao, J., Chang, K. S., Look, T., Whisenant, E., Raimondi, S., et al. (1992). Identification of breakpoints in t(821) acute myelogenous leukemia and isolation of a fusion transcript, AML1/ETO, with similarity to a drosophila segmentation gene, runt. Blood, 80(7), 1825-31.
| |
[b24]via grobid |
Tobal, K., Newton, J., Macheta, M., Chang, J., Morgenstern, G., Evans, P. A. S., et al. (2000). Molecular quantitation of minimal residual disease in acute myeloid leukemia with t(821) can identify patients in durable remission and predict clinical relapse. Blood, 95(3), 815-9.
| |
[b25]via grobid |
Krauter, J., Görlich, K., Ottmann, O., Lübbert, M., Döhner, H., Heit, W., et al. (2003). Prognostic value of minimal residual disease quantification by real-time reverse tran- scriptase polymerase chain reaction in patients with core binding factor leukemias. J Clin Oncol, 21(23), 4413-22.
| |
[b26]via grobid |
Buonamici, S., Ottaviani, E., Testoni, N., Montefusco, V., Visani, G., Bonifazi, F., et al. (2002). Real-time quantitation of minimal residual disease in inv(16)-positive acute myeloid leukemia may indicate risk for clinical relapse and may identify patients in a curable state. Blood, 99(2), 443-9.
| |
[b27]via grobid |
Grimwade, D., Jovanovic, J. V., Hills, R. K., Nugent, E. A., Patel, Y., Flora, R., et al. (2009). Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy. J Clin Oncol, 27(22), 3650-8.
| |
[b28]via grobid |
Pui, C. H., Relling, M. V., & Downing, J. R. (2004). Acute lymphoblastic leukemia. N Engl J Med, 350(15), 1535-48.
| |
[b29]via grobid |
Wetzler, M., Dodge, R. K., Mrozek, K., Carroll, A. J., Tantravahi, R., Block, A. W., et al. (1999). Prospective karyotype analysis in adult acute lymphoblastic leukemia: the cancer and leukemia Group B experience. Blood, 93(11), 3983-93.
| |
|
| ||